Enanta Pharmaceuticals | ENTA - Equity Capital And Reserves


Enanta Pharmaceuticals reported $126.59M in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
AbbVie USD -5.94B 721M Jun/2026
Amgen USD 11.69B 2.5B Jun/2026
Anika Therapeutics USD 137.28M 3.38M Jun/2026
Arrowhead Research USD 465.53M 148.45M Jun/2026
AstraZeneca USD 50.3B 2.96B Jun/2026
BioCryst Pharmaceuticals USD -454.29M 99.55M Jun/2026
Biogen USD 18.85B 196.3M Jun/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Enanta Pharmaceuticals USD 126.59M 61.87M Dec/2025
Gilead Sciences USD 11.74B 11.77B Jun/2026
GlaxoSmithKline GBP 17.64B 223M Jun/2026
Halozyme Therapeutics USD 143.54M 76.09M Jun/2026
Heron Therapeutics USD 6.91M 2.23M Jun/2026
Immunic USD 151.23M 157.91M Mar/2026
Incyte USD 6.34B 721.58M Jun/2026
Insmed USD 757.49M 52.64M Jun/2026
Ionis Pharmaceuticals USD 439.74M 51.68M Jun/2026
J&J USD 84.97B 3.78B Jun/2026
Karyopharm Therapeutics USD -265.65M 27.28M Mar/2026
Ligand Pharmaceuticals USD 967.52M 29.81M Jun/2026
Merck USD 41.93B 3.94B Jun/2026
Neurocrine Biosciences USD 3.69B 286.2M Jun/2026
Novartis USD 41.95B 3.02B Jun/2026
Novavax USD -190.71M 45.94M Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
PTC Therapeutics USD -165.36M 15.1M Jun/2026
Roche Holding CHF 32.69B 1.11B Jun/2026
Sarepta Therapeutics USD 1.53B 22.7M Jun/2026
Vertex Pharmaceuticals USD 20.25B 886M Jun/2026